Eli Lilly has a message for the U.S. Supreme Court: We aren’t going to take a $20 million patent loss for Cialis sitting down. Now, Lilly can count on a couple of friends ready to join the fight—and it's a fight that the rest of pharma might want to watch.
Enforcement Report - Week of March 8, 2017
On March 9, 2016, the Mumbai Patent Office’s, Dr. Ajay S. Thakar, Assistant Controller of Patents and Designs, (Mumbai Patent Office or Indian Patent Office) issued an Order granting UNICHEM LABORATORIES LIMITED (UNICHEM or Company) Indian Patent Application 1922/KOLNP/2007 that covers an extended-release composition of Alfuzosin Hydrochloride Extended-Release formulation (‘1922 India Patent Application). Recently, on January 28, 2016, the Company received Final Approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA #203192) for a generic version of Concordia Pharmaceuticals, Inc.’s (Concordia) Uroxatral® (Alfuzosin Hydrochloride) Extended-Release, Tablets 10mg (RLD) approved for the “treatment of signs and symptoms of benign prostatic hyperplasia”.
Unichem Lab`s Generic Alfuzosin Hydrochloride approved in US for treating symptoms of enlarged prostate(men)